[an error occurred while processing this directive]
BBC News
watch One-Minute World News
Last Updated: Monday, 12 March 2007, 19:09 GMT
Merck loses key US Vioxx lawsuit
Image of Vioxx
Merck faces thousands of claims relating to its bestselling Vioxx drug
A US jury has awarded damages of $20m (10.3m) against drugs giant Merck in a case arising from its withdrawn painkiller Vioxx.

The judgement means the jury may now move on to assess punitive damages against Merck.

Vioxx was pulled from the market in September 2004 after a study found it could double the risk of heart attacks.

The New Jersey jury ruled that Vioxx had contributed to a 61-year old man's heart attack.

Legal turnaround

The jury awarded $18m to Frederick Humeston, who suffered the heart attack after taking Vioxx for knee pain, and a further $2m to his wife.

This was the second case brought by Mr Humeston after an earlier suit failed.

Fresh evidence on the dangers of Vioxx prompted the new trial.

The jury in the second case found that Merck had failed to provide adequate warnings about the health risks associated with Vioxx.

Vioxx was launched in 1999 and became a best-selling anti-inflammatory drug, used primarily to treat arthritis.

International ramifications

Merck faces some 7,000 outstanding lawsuits connected to Vioxx, and experts have estimated its potential liabilities in the matter at over $5bn.

Sallie Booth, a partner at UK law firm Irwin Mitchell, which represents over 120 British claimants who used Vioxx, said the judgement was the latest in a string of US court case decisions.

"We hope that each decision will clarify the position for all parties" Ms Booth told BBC News.

Vioxx class action claim refused
22 Nov 06 |  Business
US drug company wins Vioxx case
17 Feb 06 |  Business
Vioxx court case ends in mistrial
12 Dec 05 |  Business

The BBC is not responsible for the content of external internet sites

Has China's housing bubble burst?
How the world's oldest clove tree defied an empire
Why Royal Ballet principal Sergei Polunin quit


Americas Africa Europe Middle East South Asia Asia Pacific